Research Study

Past Study: T1DIL-21

Study Status: CLOSED

Study Name: T1DIL-21

Study Focus: Type 1 Diabetes

Study Contact: To learn more, please call 1-877-854-8475 or fill out the Contact us form.

Study Purpose: To determine if a combination of an investigational drug called anti-IL-21 (NNC0114-0006) and a drug marketed for type 2 diabetes, called liraglutide, in addition to your standard treatment prescribed by your doctor, is able to preserve the function of insulin-producing cells in the pancreas.

To be enrolled in this study, you must meet certain requirements. You may be eligible to participate if you meet the associated criteria:

  • Newly diagnosed with type 1 diabetes, within the last 20 weeks
  • 18-45 years old
  • Men and women
  • BMI ≥18.5 kg/m2

Study Procedures:

  • Fasting blood draw
  • Physical exam
  • Vital signs and blood pressure
  • Electrocardiogram (ECG)
  • Mixed Meal Tolerance Test (MMTT)
  • Questionnaires

Study Duration: up to 20 months

Study Commitment:

  • 2 screening visit
  • 1 randomization visit
  • 25 clinic visits
  • 61 phone calls

Compensation offered? Yes

This study is being conducted under the direction of Dr. Richard Pratley, MD at 301 East Princeton Street, Orlando, Florida 32804.